02/10/2025 9:25 AM | Kymera Therapeutics (Subject) WELLINGTON MANAGEMENT GROUP LLP (Filed by)
| Form SCHEDULE 13G/A | |
01/14/2025 3:02 PM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/13/2025 6:00 AM | Jacobs Bruce N. (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/13/2025 6:00 AM | Kymera Therapeutics (Issuer) Mainolfi Nello (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/02/2024 6:50 PM | Esposito Pamela (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/02/2024 3:41 PM | Esposito Pamela (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2024 8:30 AM | Avoro Capital Advisors LLC (Filed by) Kymera Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024 9:52 AM | Kymera Therapeutics (Subject) WELLINGTON MANAGEMENT GROUP LLP (Filed by)
| Form SC 13G/A | |
10/31/2024 7:13 AM | Kymera Therapeutics (Filer)
| Form S-3ASR | |
10/31/2024 6:40 AM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/31/2024 6:45 AM | Kymera Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
Get the Latest News and Ratings for KYMR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
09/17/2024 5:20 PM | Esposito Pamela (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/17/2024 3:40 PM | Esposito Pamela (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024 5:31 PM | Albers Jeffrey W. (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/26/2024 3:32 PM | Horobin Joanna (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024 3:25 PM | Albers Jeffrey W. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/22/2024 4:06 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting) BIOTECHNOLOGY VALUE FUND L P (Reporting) Biotechnology Value Trading Fund OS LP (Reporting) BVF GP HOLDINGS LLC (Reporting) BVF I GP LLC (Reporting) BVF II GP LLC (Reporting) BVF INC/IL (Reporting) BVF PARTNERS L P/IL (Reporting) BVF Partners OS Ltd. (Reporting) Kymera Therapeutics (Issuer) LAMPERT MARK N (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/22/2024 3:15 PM | BAKER BROS. ADVISORS LP (Filed by) Kymera Therapeutics (Subject)
| Form SC 13D/A | |
08/22/2024 3:03 PM | 667, L.P. (Reporting) Baker Bros. Advisors LLC (0001580575) (Reporting) BAKER BROS. ADVISORS LP (Reporting) Baker Brothers Life Sciences LP (Reporting) BAKER FELIX (Reporting) BAKER JULIAN (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/20/2024 4:24 PM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/20/2024 3:31 PM | Kymera Therapeutics (Filer)
| Form 424B5 | |
08/07/2024 6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/07/2024 6:15 AM | Kymera Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/25/2024 5:12 PM | Horobin Joanna (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/23/2024 4:17 PM | Horobin Joanna (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/16/2024 5:00 PM | Gollob Jared (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/16/2024 3:28 PM | Gollob Jared (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/15/2024 3:31 PM | Gollob Jared (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/09/2024 4:15 PM | Booth Bruce (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/09/2024 3:16 PM | Atlas Venture Fund X, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/09/2024 3:18 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/28/2024 4:05 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting) BIOTECHNOLOGY VALUE FUND L P (Reporting) Biotechnology Value Trading Fund OS LP (Reporting) BVF GP HOLDINGS LLC (Reporting) BVF I GP LLC (Reporting) BVF II GP LLC (Reporting) BVF INC/IL (Reporting) BVF PARTNERS L P/IL (Reporting) BVF Partners OS Ltd. (Reporting) Kymera Therapeutics (Issuer) LAMPERT MARK N (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/28/2024 7:30 AM | Jacobs Bruce N. (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:00 PM | Kymera Therapeutics (Issuer) Morgan Leigh (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:00 PM | Kymera Therapeutics (Issuer) MARAGANORE JOHN (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:00 PM | Hrustanovic Gorjan (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:00 PM | Kymera Therapeutics (Issuer) Ridloff Elena (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:00 PM | Albers Jeffrey W. (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:00 PM | Booth Bruce (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:00 PM | Esposito Pamela (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:01 PM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
Warning: Elon’s $20k Robot Might Replace Your Nanny (Ad) Tesla’s Robot Revolution Has Begun
It’s official…
Tesla’s robot revolution is underway…
By the end of this year, Tesla plans to produce 600 new “Tesla Bots” per week…
Tech insiders believe this could be the company’s next core driver of explosive growth.
Some even believe it could be the catalyst that would push shares above the $1,000 mark.
That’s essentially a 100% increase from today’s price… just follow this link. |
06/20/2024 7:30 AM | Kymera Therapeutics (Issuer) Mainolfi Nello (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/14/2024 5:01 PM | Booth Bruce (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2024 4:14 PM | Atlas Venture Fund X, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/13/2024 4:15 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2024 4:23 PM | Atlas Venture Fund X, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2024 4:24 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024 5:36 PM | Horobin Joanna (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:27 PM | Horobin Joanna (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/23/2024 4:22 PM | Chadwick Jeremy G (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/02/2024 6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/02/2024 6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/02/2024 6:15 AM | Kymera Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
04/24/2024 3:15 PM | Kymera Therapeutics (Filer)
| Form ARS | |
04/24/2024 3:06 PM | Kymera Therapeutics (Filer)
| Form DEF 14A | |
04/24/2024 3:10 PM | Kymera Therapeutics (Filer)
| Form DEFA14A | |
04/01/2024 7:53 AM | BAKER BROS. ADVISORS LP (Reporting) Kymera Therapeutics (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
04/01/2024 7:56 AM | 667, L.P. (Reporting) Baker Bros. Advisors LLC (0001580575) (Reporting) BAKER BROS. ADVISORS LP (Reporting) Baker Brothers Life Sciences LP (Reporting) BAKER FELIX (Reporting) BAKER JULIAN (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/01/2024 7:57 AM | BAKER BROS. ADVISORS LP (Filed by) Kymera Therapeutics (Subject)
| Form SC 13D | |
04/01/2024 6:00 AM | Kymera Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/15/2024 6:23 PM | Booth Bruce (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/15/2024 3:30 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024 4:01 PM | Atlas Venture Fund X, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024 4:02 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/13/2024 6:52 PM | Booth Bruce (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/13/2024 6:53 PM | Atlas Venture Associates Opportunity I, L.P. (Reporting) Atlas Venture Associates Opportunity I, LLC (Reporting) ATLAS VENTURE ASSOCIATES X, L.P. (Reporting) Atlas Venture Associates X, LLC (Reporting) Atlas Venture Fund X, L.P. (Reporting) Atlas Venture Opportunity Fund I, L.P. (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/13/2024 3:55 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/13/2024 3:55 PM | Atlas Venture Fund X, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/12/2024 4:17 PM | Atlas Venture Fund X, L.P. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024 5:21 PM | Gollob Jared (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2024 4:47 PM | Jacobs Bruce N. (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024 4:50 PM | Gollob Jared (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/29/2024 3:34 PM | Gollob Jared (Reporting) Kymera Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/27/2024 3:22 PM | Gollob Jared (Reporting) Kymera Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |